亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Will New Treatment Options for Lupus Nephritis Be Affordable?

狼疮性肾炎 贝里穆马布 医学 系统性红斑狼疮 免疫抑制 治疗方式 皮肤病科 内科学 重症监护医学 免疫学
作者
Y K Onno Teng,Ton J. Rabelink
出处
期刊:Clinical Journal of The American Society of Nephrology [Lippincott Williams & Wilkins]
卷期号:17 (3): 340-341
标识
DOI:10.2215/cjn.00690122
摘要

In the last 2 years, two landmark papers have been published that show that the introduction of new treatment modalities (i.e., belimumab [the Belimumab International Study in Lupus Nephritis study] and voclosporin [the AURORA study]) on top of standard of care immunosuppression in lupus nephritis results in significantly higher remission rates (1,2). The expansion of the therapeutic armamentarium is a welcome addition for the treatment of patients with lupus nephritis, of whom merely 27%–35% achieve long-term remission (3,4) and 10% develop kidney failure in 5 years, increasing to 20% in 15 years (5,6). At first sight, it may come as no big surprise that intensifying immunosuppression in lupus nephritis would also result in higher remission rates, but both drugs may also have specific advantages over the use of broad-acting immunosuppressive drugs, such as cyclophosphamide, mycophenolate, and/or steroids, that constitute the backbone of the current standard of care. Belimumab is a recombinant IgG mAb that inhibits the B cell activation factor and therefore specifically targets the humoral autoimmune responses in the pathophysiology of lupus nephritis. It has been reported to have a favorable safety profile. Voclosporin is a calcineurin inhibitor that has a consistent pharmacokinetic profile and seems to have a more favorable effect on lipids and glucose metabolism than other CNIs (7). Accessibility to these new treatments will be a critical factor for future clinical implementation of these study results, and the pricing of these new drugs will most likely be an important determinant of their accessibility. In this issue of CJASN, Mandrik et al. (8) model the health economic effect of the introduction of these two new drugs for the treatment of lupus nephritis. They build their model on the basis of a US population of lupus nephritis with associated ethnic distribution and on the basis of current known pricing for belimumab and voclosporin; thus, the cost-effectiveness analysis might not be applicable in other health care systems or populations. Patients were assumed to be treated with the novel compounds for 3 years when responding, whereas treatment was assumed to be stopped after 1.5 years if no response could be detected or if side effects occurred. Then, long-term prognostics on survival and kidney failure were included in relation to known risk factors, such as response to treatment, sex, and ethnicity. Unfortunately, health-related quality-of-life (QoL) values had to be extrapolated from other lupus nephritis studies and cohorts into the model because the actual QoL data of these studies, although collected, have not been reported (yet). A positive correction to QoL values was imputed for patients on low-dose steroids or no steroids and when a patient was classified as a (partial) responder to treatment. The model of Mandrik et al. (8) demonstrates that the costs per gained quality-adjusted life year (QALY) for belimumab treatment in patients with lupus nephritis were $95,269 and $70,077 if the subcutaneous formulation will be used. The cost per gained QALY for voclosporin treatment was $150,344. It needs to be re-emphasized that the study design does not allow for a direct head-to-head comparison between the costs per QALY between belimumab and voclosporin. However, as stated before, the study was modeled on a 1.5-year treatment regime, whereas current practice is to treat lupus nephritis usually for between 3 and 5 years (9), which would bring not only voclosporin but also belimumab above the agreed threshold for willingness to pay in rare diseases of $100,000 per annum. A strong aspect of the study by Mandrik et al. (8) is that they were able to present incremental cost-effectiveness ratio outcomes for alternative scenarios: for example, belimumab and voclosporin are being used for longer or shorter periods, or in the case of voclosporin, a hypothetical permanent drop in kidney function is a side effect of calcineurin inhibition. Additionally, the authors also evaluated in a sensitivity analysis how the costs per QALY could be improved. The study of Mandril et al. (8) exposes a fundamental problem in drug development, where potential costs that can be saved in health care expenditure by a new drug are nullified by the price of this drug. In the case of voclosporin, this result is perhaps more distressing given the established efficacy of tacrolimus in the treatment of lupus nephritis (10), strongly suggesting that calcineurin inhibition in itself is most likely the underpinning mechanism of the clinical effect in the voclosporin studies. In recent years, we have learned to take value-based health care as the basis of our care system, whereas recent initiatives, such as ICHOMS, have given us a good understanding of what patients value (11). We propose that value-based pricing, which also takes into account how new drugs perform with respect to side effects and long-term safety, should serve as a basis to negotiate reasonable pricing with drug companies. This would not only increase access to new treatments for our patients but also be conditional for the sustainability of our health care system and drug development in general. Disclosures Y.K.O. Teng reports consultancy agreements with Aurinia Pharmaceuticals, GSK, KezarBio, Novartis, Otsuka Pharmaceuticals, and Vifor Pharma; research funding from Aurinia Pharmaceuticals and GlaxoSmithKline; and serving on the editorial board of Rheumatology. The work of Y.K.O. Teng is supported by Dutch Kidney Foundation grant 17OKG04 and by the Arthritis Research and Collaboration Hub (ARCH) Foundation. ARCH is funded by the Dutch Arthritis Foundation. The Leiden University Medical Center received consulting fees from Aurinia Pharmaceuticals, GSK, KezarBio, Novartis, Otsuka Pharmaceuticals, and Vifor Pharma for consultancies delivered by Y.K.O. Teng. The remaining author has nothing to disclose. Funding None.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Nole的应助被369ninja采纳,获得10
1秒前
zhiwei发布了新的文献求助10
2秒前
6秒前
拼搏碧曼完成签到,获得积分10
6秒前
CTShih的应助被369ninja采纳,获得10
16秒前
zhiwei发布了新的文献求助10
29秒前
33秒前
Orange的应助被369ninja采纳,获得10
35秒前
37秒前
威武的成协完成签到,获得积分10
43秒前
369ninja发布了新的文献求助10
44秒前
李健的小迷弟的应助被369ninja采纳,获得10
49秒前
淡水美人鱼完成签到,获得积分10
55秒前
57秒前
敏感的黄蜂完成签到,获得积分10
58秒前
在水一方的应助被科研通管家采纳,获得10
1分钟前
FashionBoy的应助被369ninja采纳,获得10
1分钟前
zhiwei发布了新的文献求助30
1分钟前
1分钟前
不安平松完成签到,获得积分10
1分钟前
CTShih的应助被369ninja采纳,获得10
1分钟前
jialinding发布了新的文献求助10
1分钟前
小巧的水杯完成签到 ,获得积分10
1分钟前
obaica完成签到,获得积分10
1分钟前
zhiwei发布了新的文献求助10
1分钟前
1分钟前
细腻海瑶完成签到,获得积分10
1分钟前
zhiwei发布了新的文献求助10
1分钟前
2分钟前
orixero的应助被369ninja采纳,获得10
2分钟前
悦耳的翠绿完成签到,获得积分10
2分钟前
小新小新完成签到 ,获得积分10
2分钟前
Nole的应助被369ninja采纳,获得10
2分钟前
2分钟前
tszjw168完成签到 ,获得积分10
2分钟前
Owen的应助被369ninja采纳,获得10
2分钟前
2分钟前
愉快飞薇完成签到,获得积分10
2分钟前
zhiwei发布了新的文献求助10
2分钟前
感动的天德完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808464
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557361
邀请新用户注册赠送积分活动 2478958